33 results
Thumbnail

D1.327 - Genetic Analysis of Children with Suspected Immunodeficiency: Mimickers of Inborn Errors of Immunity

Thumbnail

D1.329 - Late-Childhood Diagnosis of DNA Methyltransferase 3B Deficiency-ICF1 Syndrome

Thumbnail

D1.322 - Clinical Cardiovascular Safety Assessment of Oral Deucrictibant

Thumbnail

D1.323 - Assessing Immune Responses to Conjugate Pneumococcal Vaccination in Infants with Transient and Unclassified Hypogammaglobulinemia:Insights from a Tertiary Pediatric Center

Thumbnail

D1.324 - JAK Inhibitors in the Treatment of Chronic Mucocutaneous Candidiasis in a Patient with STAT1 Gain-of-Function Mutation

Thumbnail

D1.326 - Behind The Scenes: Primary Immunodeficiencies in Pediatric Eosinophilic Gastrointestinal Diseases

Thumbnail

D1.328 - CARD11 Dominant-Negative Mutation Presenting with Early Severe Bacterial Sepsis, Viral Susceptibility, and Alopecia Totalis in a Child

Thumbnail

D1.330 - Two different clinical presentations, two same immunological features in Purin nucleoside phosporilase deficiency

Thumbnail

D1.331 - Analysis of early complement parameters and C1INH values in newborns with a positive family history of HAE-C1INH

Thumbnail

D1.333 - Digital clinical registry pilot for hereditary angioedema: standardized monthly real-world monitoring of C1 inhibitor deficiency in Serbia

Thumbnail

D1.334 - Association of Multiple Endocrinopaties with Immune Dysregulation, Allergies and Primary Immunodeficiency

Thumbnail

D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project

Thumbnail

D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child